Insulet (NASDAQ:PODD) Price Target Raised to $317.00 at Morgan Stanley

Insulet (NASDAQ:PODD) had its price target lifted by investment analysts at Morgan Stanley from $234.00 to $317.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. Morgan Stanley’s target price points to a potential upside of 15.23% from the company’s current price.

PODD has been the topic of a number of other research reports. Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Barclays increased their price objective on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective on the stock. Finally, UBS Group raised their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Down 0.2 %

PODD stock opened at $275.10 on Monday. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet has a fifty-two week low of $156.00 and a fifty-two week high of $279.40. The firm’s 50-day simple moving average is $234.83 and its 200 day simple moving average is $206.03. The stock has a market cap of $19.29 billion, a PE ratio of 47.11, a price-to-earnings-growth ratio of 5.00 and a beta of 1.22.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently made changes to their positions in PODD. Janney Montgomery Scott LLC raised its holdings in shares of Insulet by 34.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 10,060 shares of the medical instruments supplier’s stock worth $1,724,000 after purchasing an additional 2,573 shares in the last quarter. Sei Investments Co. increased its position in shares of Insulet by 16.2% in the first quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock worth $2,019,000 after acquiring an additional 1,639 shares in the last quarter. Inspire Investing LLC increased its position in shares of Insulet by 26.0% in the first quarter. Inspire Investing LLC now owns 2,581 shares of the medical instruments supplier’s stock worth $442,000 after acquiring an additional 533 shares in the last quarter. Headlands Technologies LLC increased its position in shares of Insulet by 373.9% in the first quarter. Headlands Technologies LLC now owns 1,872 shares of the medical instruments supplier’s stock worth $321,000 after acquiring an additional 1,477 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in shares of Insulet by 3.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 78,435 shares of the medical instruments supplier’s stock worth $13,444,000 after acquiring an additional 2,847 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.